文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

成人脓毒性休克早期启动低剂量氢化可的松治疗:一项随机临床试验

Early initiation of low-dose hydrocortisone treatment for septic shock in adults: A randomized clinical trial.
PubMed 文献 · Am J Emerg Med · 2017-06-05
一句话结论成人脓毒性休克中,与升压药同时启动低剂量氢化可的松,未降低28天死亡率、住院死亡率或ICU及住院时间。

该安慰剂对照随机临床试验纳入118例成人脓毒性休克患者,随机分为氢化可的松组(n=58)与生理盐水组(n=60),研究药物与升压药同时启动。主要终点28天死亡率、次要终点休克逆转、住院死亡率及ICU和住院时间在两组间均无显著差异(休克逆转比例P=0.602)。作者结论认为早期启动低剂量氢化可的松未降低死亡风险及ICU或住院时间。

要点

  • 118例成人脓毒性休克患者随机接受氢化可的松(n=58)或生理盐水(n=60),药物与升压药同时启动。
  • 主要终点28天死亡率两组无显著差异,住院全因死亡率亦无显著差异。
  • 休克逆转比例两组相似(P=0.602)。
  • ICU住院时间与住院时间两组无显著差异。
  • 作者结论:早期启动低剂量氢化可的松未降低死亡率及ICU或住院时间。

适用人群与场景

  • 成人脓毒性休克患者,共118例纳入研究。

处置流程与药物剂量

  • 氢化可的松组(n=58)与生理盐水组(n=60)的研究药物均与升压药同时启动。

研究设计与关键结果

  • 研究类型为安慰剂对照随机临床试验,纳入118例成人脓毒性休克患者,随机分为氢化可的松组(n=58)与生理盐水组(n=60),研究药物与升压药同时启动。
  • 主要终点28天死亡率:氢化可的松组与生理盐水组无显著差异。
  • 次要终点:休克逆转比例两组相似(P=0.602);住院全因死亡率、ICU住院时间及住院时间两组均无显著差异。
  • 作者结论:早期启动低剂量氢化可的松未降低成人脓毒性休克患者的死亡风险及ICU或住院时间。

证据类型、等级与局限

  • 证据类型:安慰剂对照随机临床试验。
  • 试验注册号:NCT02580240。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论认为,成人脓毒性休克中与升压药同时早期启动低剂量氢化可的松未降低28天死亡率、住院死亡率及ICU或住院时间。
  • 原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Physiologic dose hydrocortisone is part of the suggested adjuvant therapies for patients with septic shock. However, the association between the corticosteroid therapy and mortality in patients with septic shock is still not clear. Some authors considered that the mortality is related to the time frame between development of septic shock and start of low dose hydrocortisone. Thus we designed a placebo-controlled, randomized clinical trial to assess the importance of early initiation of low dose hydrocortisone for the final outcome.

METHODS: A total of 118 patients with septic shock were recruited in the study. All eligible patients were randomized to receive hydrocortisone (n=58) or normal saline (n=60). The study medication (hydrocortisone and normal saline) was initiated simultaneously with vasopressors. The primary end-point was 28-day mortality. The secondary end-points were the reversal of shock, in-hospital mortality and the duration of ICU and hospital stay.

RESULTS: The proportion of patients with reversal of shock was similar in the two groups (P=0.602); There were no significant differences in 28-day or hospital all-cause mortality; length of stay in the ICU or hospital between patients treated with hydrocortisone or normal saline.

CONCLUSION: The early initiation of low-dose of hydrocortisone did not decrease the risk of mortality, and the length of stay in the ICU or hospital in adults with septic shock.

TRIAL REGISTRATION: www.clinicaltrials.govNCT02580240.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Lv QQ, Gu XH, Chen QH, et al. Early initiation of low-dose hydrocortisone treatment for septic shock in adults: A randomized clinical trial. Am J Emerg Med. 2017. PMID: 28615145. doi:10.1016/j.ajem.2017.06.004

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。